COCP
Cocrystal Pharma, Inc.
Biotechnology
Market Cap$18M
5Y Perf.-93.1%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
COCP vs RLAY
Revenue, margins, valuation, and 5-year total return — side by side.
RLAY
Relay Therapeutics, Inc.
Biotechnology
Market Cap$2.37B
5Y Perf.-64.7%
COCP vs RLAY — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | COCP | RLAY |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $18M | $2.37B |
| Revenue (TTM) | $0.00 | $11M |
| Net Income (TTM) | $-10M | $-273M |
| Gross Margin | — | 66.3% |
| Operating Margin | — | -27.8% |
| Total Debt | $2M | $32M |
| Cash & Equiv. | $10M | $84M |
COCP vs RLAY — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
COCP
RLAY
| Stock | Jul 20 | May 26 | Return |
|---|---|---|---|
| Cocrystal Pharma, I… (COCP) | 100 | 6.9 | -93.1% |
| Relay Therapeutics,… (RLAY) | 100 | 35.3 | -64.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: COCP vs RLAY
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: RLAY leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and recent price momentum and sentiment. Cocrystal Pharma, Inc. is the stronger pick specifically for profitability and margin quality and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
COCP
Cocrystal Pharma, Inc.
The Income Pick
COCP is the clearest fit if your priority is income & stability and growth exposure.
- beta 1.36
- EPS growth 49.2%
- Lower volatility, beta 1.36, Low D/E 19.0%, current ratio 4.77x
Best for: income & stability and growth exposure
RLAY
Relay Therapeutics, Inc.
The Long-Run Compounder
RLAY carries the broadest edge in this set and is the clearest fit for long-term compounding.
- -64.3% 10Y total return vs COCP's -99.4%
- 53.4% revenue growth vs COCP's 48.4%
- +324.1% vs COCP's -11.5%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | RLAY | 53.4% revenue growth vs COCP's 48.4% |
| Quality / Margins | COCP | 4.0% margin vs RLAY's -25.5% |
| Stability / Safety | COCP | Beta 1.36 vs RLAY's 1.77 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | RLAY | +324.1% vs COCP's -11.5% |
| Efficiency (ROA) | RLAY | -40.1% ROA vs COCP's -92.6%, ROIC -37.3% vs -8.0% |
COCP vs RLAY — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLRLAYLAGGINGCOCP
COCPCocrystal Pharma, Inc.
1leads
RLAYRelay Therapeutics, I…
2leads
6 Total Categories
CATEGORYLEADERvs COCPMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
COCP1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
RLAY7/8
Total Returns1Y, 3Y, 5Y total returns with dividends
RLAY6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
COCP leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
RLAY and COCP operate at a comparable scale, with $11M and $0 in trailing revenue.
| Metric | COCPCocrystal Pharma,… | RLAYRelay Therapeutic… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $11M |
| EBITDAEarnings before interest/tax | -$10M | -$298M |
| Net IncomeAfter-tax profit | -$10M | -$273M |
| Free Cash FlowCash after capex | -$10M | -$213M |
| Gross MarginGross profit ÷ Revenue | — | +66.3% |
| Operating MarginEBIT ÷ Revenue | — | -27.8% |
| Net MarginNet income ÷ Revenue | — | -25.5% |
| FCF MarginFCF ÷ Revenue | — | -20.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -60.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +61.2% | +10.9% |
COCP leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — COCP and RLAY each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | COCPCocrystal Pharma,… | RLAYRelay Therapeutic… |
|---|---|---|
| Market CapShares × price | $18M | $2.4B |
| Enterprise ValueMkt cap + debt − cash | $10M | $2.3B |
| Trailing P/EPrice ÷ TTM EPS | -0.81x | -7.77x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 154.15x |
| Price / BookPrice ÷ Book value/share | 1.49x | 3.79x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — COCP and RLAY each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
RLAY leads this category, winning 7 of 8 comparable metrics.
Profitability & Efficiency
RLAY delivers a -43.9% return on equity — every $100 of shareholder capital generates $-44 in annual profit, vs $-126 for COCP. RLAY carries lower financial leverage with a 0.06x debt-to-equity ratio, signaling a more conservative balance sheet compared to COCP's 0.19x. On the Piotroski fundamental quality scale (0–9), RLAY scores 5/9 vs COCP's 1/9, reflecting solid financial health.
| Metric | COCPCocrystal Pharma,… | RLAYRelay Therapeutic… |
|---|---|---|
| ROE (TTM)Return on equity | -126.1% | -43.9% |
| ROA (TTM)Return on assets | -92.6% | -40.1% |
| ROICReturn on invested capital | -8.0% | -37.3% |
| ROCEReturn on capital employed | -91.6% | -42.7% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 5 |
| Debt / EquityFinancial leverage | 0.19x | 0.06x |
| Net DebtTotal debt minus cash | -$8M | -$52M |
| Cash & Equiv.Liquid assets | $10M | $84M |
| Total DebtShort + long-term debt | $2M | $32M |
| Interest CoverageEBIT ÷ Interest expense | — | — |
RLAY leads this category, winning 7 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
RLAY leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in RLAY five years ago would be worth $4,241 today (with dividends reinvested), compared to $878 for COCP. Over the past 12 months, RLAY leads with a +324.1% total return vs COCP's -11.5%. The 3-year compound annual growth rate (CAGR) favors RLAY at 5.0% vs COCP's -20.4% — a key indicator of consistent wealth creation.
| Metric | COCPCocrystal Pharma,… | RLAYRelay Therapeutic… |
|---|---|---|
| YTD ReturnYear-to-date | +40.4% | +52.9% |
| 1-Year ReturnPast 12 months | -11.5% | +324.1% |
| 3-Year ReturnCumulative with dividends | -49.6% | +15.6% |
| 5-Year ReturnCumulative with dividends | -91.2% | -57.6% |
| 10-Year ReturnCumulative with dividends | -99.4% | -64.3% |
| CAGR (3Y)Annualised 3-year return | -20.4% | +5.0% |
RLAY leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — COCP and RLAY each lead in 1 of 2 comparable metrics.
Risk & Volatility
COCP is the less volatile stock with a 1.36 beta — it tends to amplify market swings less than RLAY's 1.77 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RLAY currently trades 72.3% from its 52-week high vs COCP's 52.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | COCPCocrystal Pharma,… | RLAYRelay Therapeutic… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.36x | 1.77x |
| 52-Week HighHighest price in past year | $2.67 | $17.31 |
| 52-Week LowLowest price in past year | $0.86 | $2.67 |
| % of 52W HighCurrent price vs 52-week peak | +52.1% | +72.3% |
| RSI (14)Momentum oscillator 0–100 | 54.0 | 45.9 |
| Avg Volume (50D)Average daily shares traded | 2.9M | 3.1M |
Evenly matched — COCP and RLAY each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | COCPCocrystal Pharma,… | RLAYRelay Therapeutic… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $21.60 |
| # AnalystsCovering analysts | — | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
RLAY leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). COCP leads in 1 (Income & Cash Flow). 2 tied.
Best OverallRelay Therapeutics, Inc. (RLAY)Leads 2 of 6 categories
Loading custom metrics...
COCP vs RLAY: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is COCP or RLAY a better buy right now?
Analysts rate Relay Therapeutics, Inc.
(RLAY) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — COCP or RLAY?
Over the past 5 years, Relay Therapeutics, Inc.
(RLAY) delivered a total return of -57. 6%, compared to -91. 2% for Cocrystal Pharma, Inc. (COCP). Over 10 years, the gap is even starker: RLAY returned -64. 3% versus COCP's -99. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — COCP or RLAY?
By beta (market sensitivity over 5 years), Cocrystal Pharma, Inc.
(COCP) is the lower-risk stock at 1. 36β versus Relay Therapeutics, Inc. 's 1. 77β — meaning RLAY is approximately 30% more volatile than COCP relative to the S&P 500. On balance sheet safety, Relay Therapeutics, Inc. (RLAY) carries a lower debt/equity ratio of 6% versus 19% for Cocrystal Pharma, Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — COCP or RLAY?
Cocrystal Pharma, Inc.
(COCP) is the more profitable company, earning 0. 0% net margin versus -1800. 6% for Relay Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: COCP leads at 0. 0% versus -1971. 6% for RLAY. At the gross margin level — before operating expenses — RLAY leads at 76. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — COCP or RLAY?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is COCP or RLAY better for a retirement portfolio?
For long-horizon retirement investors, Cocrystal Pharma, Inc.
(COCP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Relay Therapeutics, Inc. (RLAY) carries a higher beta of 1. 77 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (COCP: -99. 4%, RLAY: -64. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between COCP and RLAY?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: COCP is a small-cap quality compounder stock; RLAY is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.